Post Author: Chris Apfel, MD, PhD, MBA
Chris Apfel is a physician and clinical researcher with over 100 published papers, widely recognized for his data-driven contributions in anesthesia and oncology. He developed the Apfel score, a clinical tool used globally to predict postoperative nausea and vomiting, which has been validated in multiple studies. Dr. Apfel currently serves as chairman and CEO of SageMedic Corp., a company at the forefront of functional precision medicine in oncology.
Under his leadership, SageMedic Corp. is revolutionizing cancer treatment outcomes through the SAGE Oncotest™, an AI-augmented, in-vitro, 3D microtumor platform. This technology uses a patient’s live cancer tissue to predict drug resistance and identify the most effective treatment within 7 to 10 days. The test more than doubles a patient’s current likelihood of receiving the best therapy, improving both life expectancy and quality of life.
Dr. Apfel’s academic career includes appointments at prominent institutions. From 2003 to 2006, he served as assistant professor in the Department of Anesthesia and Perioperative Medicine at the University of Louisville. In 2006, he joined the University of California, San Francisco (UCSF) as associate professor in the Department of Anesthesia and Perioperative Care. Since 2010, he has also served as associate adjunct professor in the Department of Epidemiology and Biostatistics at UCSF.
To learn more or get in touch, connect with Chris Apfel, MD on LinkedIn, follow SageMedic Corp on LinkedIn, or visit the SageMedic Facebook page.
Chris Apfel is a physician and clinical researcher with over 100 published papers, widely recognized for his data-driven contributions in anesthesia and oncology. He developed the Apfel score, a clinical tool used globally to predict postoperative nausea and vomiting, which has been validated in multiple studies. Dr. Apfel currently serves as chairman and CEO of SageMedic Corp., a company at the forefront of functional precision medicine in oncology.
Under his leadership, SageMedic Corp. is revolutionizing cancer treatment outcomes through the SAGE Oncotest™, an AI-augmented, in-vitro, 3D microtumor platform. This technology uses a patient’s live cancer tissue to predict drug resistance and identify the most effective treatment within 7 to 10 days. The test more than doubles a patient’s current likelihood of receiving the best therapy, improving both life expectancy and quality of life.
Dr. Apfel’s academic career includes appointments at prominent institutions. From 2003 to 2006, he served as assistant professor in the Department of Anesthesia and Perioperative Medicine at the University of Louisville. In 2006, he joined the University of California, San Francisco (UCSF) as associate professor in the Department of Anesthesia and Perioperative Care. Since 2010, he has also served as associate adjunct professor in the Department of Epidemiology and Biostatistics at UCSF.
To learn more or get in touch, connect with Chris Apfel, MD on LinkedIn, follow SageMedic Corp on LinkedIn, or visit the SageMedic Facebook page.
Functional precision oncology is taking precision medicine to the next level. It is changing the way we fight cancer by testing a patient’s live tumor outside the body to determine the treatments most likely to work. This approach promises to double cancer response rates, improve survival, and reduce costs. It’s personal, data-driven, and long overdue, yet most cancer centers still don’t offer it.
Even many doctors are unaware that the standard …
Read more…
